Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06949306
Starting soon Not applicable

Intervention Study on Digital Health Management

NCT06949306 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai 10th People's Hospital
Phase
Not applicable
Started
2025-07-01
Last updated
2025-04-29

Condition(s) studied

HypertensionHyperlipidemia

Investigational drug(s) / intervention(s)

Bracelet, assistant, APP: the "golden triangle" of smart life

Bracelet, assistant, APP: the "golden triangle" of smart life: The lifestyle intervention was carried out through the bracelet, Little Assistant and Keyhealth APP for 24 weeks, and the daily data synchronization of the APP and weekly AI feedback were performed. After 24 weeks, blood glucose, blood lipid, blood pressure, CAI and other indicators were monitored.

Study summary

The aim of this study is to construct a digital precision intervention system for cardiometabolism disorders based on the characteristics of the Chinese population, focusing on the core components of metabolic syndrome such as hypertension, hyperglycemia, and obesity. Through dynamic monitoring of wearable devices, the individualized risk factors (including genetic predisposition, lifestyle, and psychological factors) of metabolic disorders were systematically analyzed, and dynamic intervention strategies were formulated accordingly. The closed-loop management of "monitor-feedback-optimization" based on the digital platform will provide patients with one-stop metabolic risk assessment and panoramic health management plan, realizing a paradigm shift from "generalized intervention" to "precise regulation". By reducing the abnormal fluctuations of key metabolic indicators such as blood pressure, blood glucose, and blood lipids, the risk of cardiovascular events will eventually be reduced, the long-term quality of life of patients will be improved, and a practical path of "digital therapy" can be promoted for the prevention and control of chronic diseases in China

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:1. Age 18-65 years old; 2. Meet one of the following three conditions: 1. Diastolic hypertension (systolic blood pressure \< 140 MMHG and diastolic blood pressure ≥90mmHg) 2. Glycosylated hemoglobin (6.0-6.5) 3. Obesity (BMI≥28kg/m²) 4. Mild hyperlipemia: total cholesterol (TC) ≥5.2 mmol/L and \< 6.2 mmol/L, or low-density lipoprotein cholesterol (LDL-C) ≥3.4 mmol/L and \< 4.1 mmol/L 3. Antihypertensive or lipid-lowering medications have not been started 4. Use a smartphone and volunteer Exclusion Criteria: 1. Complicated with chronic liver and kidney disease, coronary heart disease, heart failure and severe valvular disease 2. Previous cardiovascular and cerebrovascular events 3. Diastolic blood pressure ≥99mmHg 4. Glycated hemoglobin ≥6.5 5. Other life expectancy such as cancer is less than 5 years 6. Participate in other clinical trials

Primary outcome measure(s)

  • Changes in diastolic blood pressure after 24 weeks — 24 weeks following intervention

Trial sites (1)

FacilityCityRegionStatus
Department of Cardiology,Shanghai Tenth People's Hospital Shanghai Shanghai Municipality

More Shanghai 10th People's Hospital trials in China

Clinical Safety and Efficacy of Fecal Microbiota Transplantation (FMT) in the Treatment of Alzheimer's Disease Active, not recruiting
Assessment of the Effects and Safety of Spermidine Supplementation on Blood Lipids and Body Weight in Overweight or Obese Individuals With Hyperlipidemia Recruiting
Efficacy and Safety of Renal Denervation on Isolated Diastolic Hypertension Starting soon
Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease Recruiting
Multidisciplinary Diagnosis and Treatment of Polycystic Ovary Syndrome Recruiting

Other trials for the same condition

Tafolecimab in Hyperlipidemia: A Study of Different Dosing Intervals Starting soon
The Effect of Ablation Duration of Renal Denervation on Antihypertensive Efficacy Recruiting
EIT Evaluation of Different Antihypertensive Agents on the Ventilation-Perfusion Ratio in Patients With Acute Respiratory Failure Starting soon
Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia Enrolling by invitation
Sympathetic Mapping/ Ablation of Renal Nerves Trial Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06949306 on ClinicalTrials.gov ↗ ← All trials in China